^
    Back
    Association details:
    Biomarker:ESR1 mutation
    Cancer:Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.

    Published date:
    05/25/2023
    Excerpt:
    Here we present exploratory results from AURORA patients treated with first line CDK4/6i + ET….Both TP53 and acquired ESR1 mutations were associated with shorter PFS (hazard ratio [HR] 1.59 [95% CI 1.43-6.73], p=0.004 and 3.10 [95% CI 1.16-2.18], p=0.004 respectively)....Endocrine resistance status and TP53 and acquired ESR1 mutations were associated with shorter PFS.
    Secondary therapy:
    Hormone Therapy
    DOI:
    10.1200/JCO.2023.41.16_suppl.1019